Sugi Predict

Sugi Predict / Compounds / SCHEMBL906128

SCHEMBL906128

SCHEMBL906128

C[C@@H]1CNCCN1c1ccnc(OCc2cccc(Cl)c2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 13/20 0.55
▸ HTR2B P41595 4/20 0.47
▸ HTR2A P28223 3/20 0.47
▸ CHRM4 P08173 1/20 0.46
▸ ADRB1 P08588 1/20 0.46
▸ HTR1A P08908 1/20 0.46
▸ CHRM5 P08912 1/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ CHRM3 P20309 1/20 0.46
▸ FPR3 P25089 1/20 0.46
▸ HTR1D P28221 1/20 0.46
▸ HTR1B P28222 1/20 0.46
▸ HTR1E P28566 1/20 0.46
▸ GPR183 P32249 1/20 0.46
▸ HTR7 P34969 1/20 0.46
▸ HRH1 P35367 1/20 0.46
▸ DRD3 P35462 1/20 0.46
▸ HTR3A P46098 1/20 0.46
▸ SIGMAR1 Q99720 1/20 0.46
▸ GPR35 Q9HC97 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27602475 1.00 HTR2C (0.55) HTR2CHTR2BHTR2ACHRM4ADRB1
SCHEMBL906127 1.00 HTR2C (0.55) HTR2CHTR2BHTR2ACHRM4ADRB1
Hydrochloric Acid SCHEMBL27621042 0.99 HTR2C (0.54) HTR2CHTR2BHTR2ACHRM4ADRB1
SCHEMBL27602463 0.88 HTR2C (0.51) HTR2CHTR2BHTR2AHTR1AHTR7
SCHEMBL27602567 0.88 HTR2C (0.51) HTR2CHTR2BHTR2AHTR1AHTR7
SCHEMBL905816 0.84 HTR2C (0.44) HTR2CHTR2BHTR2ASLC6A4
SCHEMBL905815 0.84 HTR2C (0.44) HTR2CHTR2BHTR2ASLC6A4
SCHEMBL906027 0.82 HTR2C (0.64) HTR2CHTR2BHTR2ACHRM4ADRB1
SCHEMBL905764 0.78 HTR2C (0.61) HTR2CHTR2BHTR2AHTR6SLC6A4
SCHEMBL905766 0.78 HTR2C (0.61) HTR2CHTR2BHTR2AHTR6SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1630645-A 5-HT receptor ligands and uses thereof PFIZER (US) 2005-06-22 — — CN claimed
US-20050054656-A1 5-HT receptor ligands and uses thereof PFIZER INC 2005-03-10 — — US claimed
US-6825198-B2 FOR THERAPY OF SEXUAL DISORDER PFIZER INC 2004-11-30 — — US claimed
EP-1401819-A1 5-HT RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2004-03-31 — — EP claimed
US-20030105106-A1 5-HT receptor ligands and uses thereof CHIANG PHOEBE (US) 2003-06-05 — — US claimed
WO-2003000663-A1 5-HT RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2003-01-03 — — WO claimed
US-20110152272-A1 Treatment Of Incontinence PFIZER INC 2011-06-23 — — US disclosed
EP-2277513-A2 Treatment of incontinence with 5htc2 agonists Pfizer Inc. (US) 2011-01-26 — — EP disclosed
CN-1780612-B Treatment of incontinence with 5HT2C agonists. PFIZER 2010-12-01 — — CN disclosed
US-20080146583-A1 Treatment of Incontinence PFIZER INC 2008-06-19 — — US disclosed
CN-1780612-A Treatment of incontinence with 5HT2C agonists. PFIZER (US) 2006-05-31 — — CN disclosed
US-6995159-B2 5-HT receptor ligands and uses thereof PFIZER INC. (US) 2006-02-07 — — US disclosed
EP-1620081-A2 TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS Pfizer Limited (GB) 2006-02-01 — — EP disclosed
US-20050032809-A1 5-HT receptor ligands and uses thereof PFIZER INC 2005-02-10 — — US disclosed
US-6825198-B2 FOR THERAPY OF SEXUAL DISORDER PFIZER INC 2004-11-30 — — US disclosed
US-20040235856-A1 Treatment of incontinence PFIZER INC 2004-11-25 — — US disclosed
WO-2004096196-A2 TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS PFIZER LIMITED (GB) 2004-11-11 — — WO disclosed
EP-1401819-A1 5-HT RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2004-03-31 — — EP disclosed
US-20030105106-A1 5-HT receptor ligands and uses thereof CHIANG PHOEBE (US) 2003-06-05 — — US disclosed
WO-2003000663-A1 5-HT RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2003-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032809-A1 5-HT receptor ligands and uses thereof HTR2A, HTR1A, HTR5A HTR2C 4/4885HTR2B 5/4885HTR2A 1/4885
US-20040235856-A1 Treatment of incontinence HTR2C, HTR5A, ADRA2C HTR2C 1/4885HTR2B 10/4885HTR2A 6/4885
US-20030105106-A1 5-HT receptor ligands and uses thereof HTR1A, HTR2A, HTR5A HTR2C 4/4885HTR2B 7/4885HTR2A 2/4885
US-20110152272-A1 Treatment Of Incontinence HTR2C, HTR5A, ADRA2C HTR2C 1/4885HTR2B 10/4885HTR2A 6/4885
US-20080146583-A1 Treatment of Incontinence HTR2C, HTR5A, ADRA2C HTR2C 1/4885HTR2B 10/4885HTR2A 6/4885
US-20050054656-A1 5-HT receptor ligands and uses thereof HTR2A, HTR1A, HTR5A HTR2C 4/4885HTR2B 5/4885HTR2A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.